

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/V68BF2C46F8DEN.html>

Date: December 2022

Pages: 44

Price: US\$ 2,000.00 (Single User License)

ID: V68BF2C46F8DEN

Abstracts

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drugs In Development, 2022, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline landscape.

Vancomycin resistant staphylococcus infection is a condition caused by bacteria (germs). This infection occurs when bacteria, called Staphylococcus aureus or Staph, becomes resistant (not killed) to the antibiotic medicine vancomycin. Risk factors include taking strong antibiotics the wrong way may cause the bacteria to develop resistance to the antibiotics, weak immune system and staying in the hospital too long. Symptoms include fever, chills, cough, chest pain, trouble breathing, and a fast heartbeat.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under

development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of

development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Overview

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics

Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics

Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Companies Involved
in Therapeutics Development

Amprologix Ltd

CrystalGenomics Inc

Destiny Pharma Plc

Lysimmune BioScience

Sano Chemicals Inc

TAXIS Pharmaceuticals Inc

TGV-Inhalonix Inc

Therapeutic Systems Research Laboratories Inc

Wockhardt Ltd

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drug Profiles

APY-281 - Drug Profile

Product Description

Mechanism Of Action

CG-549 - Drug Profile

Product Description

Mechanism Of Action

Epidermicin NI-01 - Drug Profile

Product Description

Mechanism Of Action

exeporfinium chloride - Drug Profile

Product Description

Mechanism Of Action

LI-03 - Drug Profile

Product Description

Mechanism Of Action

Mul-1867 - Drug Profile

Product Description

Mechanism Of Action

MUT-001 - Drug Profile

Product Description

Mechanism Of Action

Small Molecule for Gram-Positive Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit crtN for Staphylococcus aureus Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit PBP2 for Gram-Positive Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit PBP2a for Gram-Positive Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Gram Positive Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for MRSA and VRSA Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit Methionine tRNA Ligase for Gram Positive Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

TXA-709 - Drug Profile

Product Description
Mechanism Of Action
WCK-4086 - Drug Profile
Product Description
Mechanism Of Action
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued
Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Amprologix Ltd, 2022

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by CrystalGenomics Inc, 2022

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Destiny Pharma Plc, 2022

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Lysimmune BioScience, 2022

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Sano Chemicals Inc, 2022

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TAXIS Pharmaceuticals Inc, 2022

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TGV-Inhalonix Inc, 2022

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, 2022

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Wockhardt Ltd, 2022

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects, 2022

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Vancomycin-Resistant *Staphylococcus aureus* (VRSA) Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/V68BF2C46F8DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V68BF2C46F8DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

